---
title: "Kratom, 7-OH, and MGPI: What clinicians need to know about use, risks, and regulation"
id: "stat-news-2-most-people-haven-t-heard-of-kratom-what-is-it-and-who-s-using-it"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-2-most-people-haven-t-heard-of-kratom-what-is-it-and-who-s-using-it"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss"
published_at: "2026-11-06T09:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Kratom, 7-OH, and MGPI: What clinicians need to know about use, risks, and regulation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-2-most-people-haven-t-heard-of-kratom-what-is-it-and-who-s-using-it
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss)
- **Published At:** 2026-11-06T09:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- New survey data from the Annenberg Public Policy Center found about two-thirds (66%) of Americans have never heard of **kratom**, and many users cannot distinguish natural leaf products from semi-synthetic derivatives. - **Kratom** leaves contain dozens of alkaloids; **mitragynine** is the most abundant and is a partial agonist at mu-opioid receptors, producing less receptor activation than full opioids. - Traditional kratom arrives as dried leaf powder, used as tea or capsules; low doses can act like a mild stimulant, higher doses have been reported for chronic pain management and to ease opioid withdrawal, but there are no evidence-based dosing recommendations. - Investigators and clinicians reported growing concern about semi-synthetic concentrated compounds such as **7-hydroxymitragynine (7-OH)** and **mitragynine pseudoindoxyl (MGPI)**, which are manufactured into tablets, gummies, and drinks with variable and increasingly high potencies. - **7-OH** is not present in fresh leaf but appears in dried leaf and as a metabolite of mitragynine; it is a partial mu-opioid receptor agonist and has been linked to stronger sedative effects and more severe dependence in case reports and clinical anecdotes. - The DEA has proposed regulatory actions: initially seeking bans on MGPI (and 7-OH), then updating proposals to allow limits based on ratios of metabolites to **mitragynine**; multiple states and localities have enacted emergency bans on 7-OH and, in some cases, all kratom products. - National Poison Data Center surveillance showed a 1,200% increase in kratom-related exposure reports from 2015 to 2025 (258 to 3,434). Over the same decade, 233 deaths in the poison center data involved kratom and often other substances; Florida reporting found over 580 overdose deaths involving kratom products in nearly 10 years. - Product inconsistency is common: tests indicate labeled concentrations often differ from measured levels, and some products contain unlabeled compounds, complicating safety assessments and causal attribution in toxicology. - Limited rigorous evidence exists on rates of dependence and severity of withdrawal; literature cited reports up to about 38% of users may develop use disorders in some studies, while controlled data on MGPI and 7-OH dependence remain sparse. - Investigators noted ongoing research efforts: a Yale-led study on 7-OH tolerance and withdrawal is underway; pending DEA rulemaking and wrongful-death litigation have brought additional scrutiny but leave several safety questions unresolved.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [chronic disease](https://www.statnews.com/topic/chronic-disease/) [rare diseases](https://www.statnews.com/topic/rare-diseases/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [Health](https://www.statnews.com/category/health/) # Most people haven’t heard of kratom. What is it, and who’s using it? ## Kratom and 7-OH pose a real risk of addiction, but they also appear to help some with chronic pain * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/11/kratomexplainer-645x645.jpg) Camille MacMillan/STAT ![](https://www.statnews.com/wp-content/uploads/2026/01/theresa-gaffney-avatar-round-80x80.png) By [Theresa Gaffney](https://www.statnews.com/staff/theresa-gaffney/) Nov. 6, 2026 Addiction Reporter ![](https://www.statnews.com/wp-content/uploads/2026/01/theresa-gaffney-avatar-round-80x80.png) [Theresa Gaffney](https://www.statnews.com/staff/theresa-gaffney/) 1. [](https://www.linkedin.com/in/theresa-gaffney-2484b494/ "Linkedin") 2. [](https://x.com/_gaffknee "X") theresa.gaffney@statnews.com Theresa covers substance use and addiction and co-writes the [Morning Rounds](https://www.statnews.com/signup/morning-rounds/) newsletter. You can reach Theresa on Signal at theresagaff.97. [Get email alerts for Theresa GaffneySigned up for email alertsRemove email alerts](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/?utm_campaign=rss) [Subscribe](https://www.statnews.com/stat-plus/) or [log in](https://www.statnews.com/login/) to STAT+ to unlock email alerts Over the last few years, the [kratom plant and supplements made from it](https://www.statnews.com/2026/09/21/kratom-withdrawal-addiction-centers-report-surge/) have garnered increasing attention from public health leaders. This broad category of products, which largely skirts any regulation, has seen major surges in potency, while becoming omnipresent on smoke shop and [gas station shelves](https://www.statnews.com/2026/01/28/how-gas-station-drugs-remain-legal/). Health officials have warned that concentrated compounds like 7-hydroxymitragynine (7-OH) are an emerging public health threat, and [federal policies to limit their availability are pending](https://www.statnews.com/2026/09/30/dea-proposal-7-oh-kratom-schedule-1-drug/). In the meantime, multiple states and smaller localities have issued emergency bans on 7-OH, and in some cases, on all kratom products. Despite the messaging and rising use, few Americans are familiar with kratom or the newer derivative products. They’re made with compounds that have scientific names like 7-OH, mitragynine pseudoindoxyl (MGPI) and dihydro-7-hydroxy mitragynine (MGM-15) but are often sold on shelves with names like Dozo Perks, Roxy, and UltraOhmz Pseudo Supreme. New survey data from the [Annenberg Public Policy Center](https://www.annenbergpublicpolicycenter.org/wp-content/uploads/aw30-do02k-topline-kratom-v2.pdf) show about two-thirds (66%) of Americans have never heard of kratom. Among those who had at least some familiarity, few understood the difference between its natural leaf form and more synthetic products. Advertisement That confusion carries over to the associated risks. In the survey of nearly 2,000 people, 66% were unsure if kratom products posed a serious public safety hazard. And most people didn’t understand health secretary Robert F. Kennedy Jr.’s stance on regulation — a question that’s become complicated by [repeated reports](https://www.nytimes.com/2026/06/15/us/politics/kratom-trump-administration.html) of [kratom industry lobbying influence](https://www.nytimes.com/2026/10/28/us/politics/trump-opioid-kratom.html) on the DEA’s proposed action. STAT spoke with researchers and people who use or have used kratom and 7-OH to get a full picture of what these products are, along with their potential risks and benefits. ## What is kratom? To an untrained eye, a kratom leaf might resemble a bay leaf. It grows on evergreen trees indigenous to Southeast Asian countries, including Thailand, Malaysia, and Indonesia. For centuries, people there have chewed the leaf or brewed it into tea for its stimulant-like effects. Advertisement Kratom (pronounce it with a hard or soft “a,” your choice) contains dozens of alkaloids, but mitragynine is the most abundant and the best understood. It acts as a partial agonist that binds to mu-opioid receptors in the nervous system. (Partial agonists produce less of a response from the receptor than full agonists, such as fentanyl or oxycodone.) The first kratom products to arrive in the U.S. were made by drying and grinding up those leaves to create a matcha-like powder often used as a tea or swallowed in a capsule. In low quantities, it acts as a mild stimulant that can appear [similar to coffee](https://pmc.ncbi.nlm.nih.gov/articles/PMC10939942/). In higher doses, people have used kratom to stave off chronic pain and even to help ease withdrawal from opioids. (There are no evidence-based dose recommendations, and there’s a lot of variation in both product potency and personal preference.) Related Story ![](https://www.statnews.com/wp-content/uploads/2026/09/AP26267511904962-768x432.jpg) ### [Kratom and 7-OH should be regulated, experts agree. They’re split on how](https://www.statnews.com/2026/09/30/dea-proposal-7-oh-kratom-schedule-1-drug/) “We call it swamp water, so that should give you a good visual,” said Madalyn Sklar, who uses kratom to ease chronic pain caused by degenerative disc disease, and hosts two podcasts on kratom. The first time Sklar drank the bitter tea made from kratom powder, she added orange juice as a sweetener, but still “it was so gross that I almost puked.” She’s taken it nearly every day since 2019, and says the results are better than when she was on meds like OxyContin and gabapentin. She takes two teaspoons of powder — which works out to about 70-75 milligrams of mitragynine — every six hours. For her, there’s no high or euphoria. But she can do simple tasks that she couldn’t before, such as walk her dog and bend down to pick up its poop. Sklar hasn’t experienced withdrawal symptoms when she’s occasionally stopped taking kratom and returned to more traditional pain medication. Research is limited, but has found that up to [around 38% of kratom users may develop use disorders](https://www.sciencedirect.com/science/article/pii/S2772724625000770?via%3Dihub). In studies, withdrawal from kratom has appeared [mild](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/pdf/nihms-1961667.pdf) on a scale that measures clinical opioid withdrawal, with symptoms like anxiety, fatigue, gastrointestinal issues, and restlessness. Advertisement Before semi-synthetic products came onto the scene, most public health concern around kratom was directed at extracts and tinctures, recalled Sklar. Many of these products still tout mitragynine as the active ingredient, but in much more concentrated volumes than the whole leaf powder — think 100 to 300 milligrams of mitragynine in a bottle of liquid the size of a 5-hour Energy. (There are currently no federal proposals that aim to regulate concentrated mitragynine products.) “But people got really interested in the other alkaloids over time,” said Katherine Hill, an epidemiologist at the Yale School of Public Health who has studied kratom. “And specifically they got interested in 7-hydroxymitrogynine.” ## What is 7-OH? The alkaloid 7-OH does not appear in the fresh kratom leaf that people in Southeast Asia chew, according to Hill. It shows up in the dried leaf powder products, in small amounts. It’s also a metabolite, meaning that when the body absorbs mitragynine, some of it turns it into 7-OH. Once inside the body, 7-OH, like mitragynine, is a partial agonist to the mu-opioid receptor. The products made with 7-OH — including tablets, gummies, shots, and drink powders — are semi-synthetic; they contain artificially concentrated amounts of the compound. When the products first started popping up, they were often sold in tablets containing 12-14 milligrams, users said. Those can offer sedative effects and pain relief. But now, tablets containing 25, 50, and even 100 milligrams of 7-OH are available. Related Story ![](https://www.statnews.com/wp-content/uploads/2026/09/kratom-768x432.jpg) ### [Addiction clinics see rising cases of kratom and 7-OH withdrawal](https://www.statnews.com/2026/09/21/kratom-withdrawal-addiction-centers-report-surge/) “The first time I heard of 7-OH, it was very negative,” said Twinkle VanFleet, who co-hosts a kratom podcast with Sklar. While natural kratom products carry a risk of dependence and what’s thought to be mild withdrawal at low doses, there’s [growing concern that concentrated 7-OH products are even more addictive](https://www.statnews.com/2026/09/21/kratom-withdrawal-addiction-centers-report-surge/), and that withdrawal can be as bad as coming off a traditional opioid. Hill is working on a study of 7-OH users that will look at both tolerance and withdrawal. But for now, the risks are mainly documented in case reports, series, and other anecdotal accounts. Advertisement VanFleet suffers from intense pain from an injury that led to complex regional pain syndrome, and she has a deep mistrust of the medical system. Kratom didn’t ease her symptoms, so she eventually tried 7-OH, and found comfort in what she calls “nibbles” of smaller tablets. She currently takes around 12 milligrams per day and worries about a ban by the Drug Enforcement Administration. Still, she shares concerns about the availability of higher-dose products. “I do see both sides of a lot of this,” VanFleet said. “In my perfect world, there would be 3, 5, and 10 milligram tablets, period. If even that.” Greg Kiesow had been sober from alcohol for nearly 20 years and retired for three days when he went into a smoke shop that was promoting 7-OH products. The shopkeeper had heard it was some sort of natural energy supplement, like coffee, and gave Kiesow a free sample of tablets. “I took it home, and I took it. And 10 to 15 minutes later, it wasn’t coffee. It was a very powerful opioid,” Kiesow said. Kiesow said he quickly developed an addiction. After 10 months, which he described as an extremely isolated period spent sitting on his back porch watching the birds at his bird feeder, he began to taper himself off the products. A few weeks later, he formed [Kratom Anonymous](https://www.kratom-anonymous.org/), which has 15 virtual meetings per week for people looking to quit. ## What about MGPI? As 7-OH gained popularity, newer synthetic products have continued to crop up, including some with concentrated levels of mitragynine pseudoindoxyl (MGPI), another metabolite of mitragynine. Over the summer, the DEA proposed a ban of MGPI at any quantity. But an updated proposal in October, [pushed by a lobbyist for the American Kratom Association](https://x.com/HaddowMac/status/2108901054872007078), would allow small amounts of the compound to show up in products. Instead of an outright ban, the DEA now proposes limiting both MGPI and 7-OH based on the ratio of those compounds to mitragynine in any given product. The reason for the change, according to the DEA, is that trace amounts of MGPI could appear in natural kratom. But the safety of small amounts is unclear. Test results [presented](https://www.nytimes.com/2026/10/28/us/politics/trump-opioid-kratom.html) in recent wrongful death lawsuits suggest that a natural kratom powder product, used by somebody who died after taking it, was likely contaminated with MGPI. Advertisement ## Kratom, 7-OH, and MGPI: What are the risks? As more people use kratom and other associated products, there’s a growing recognition of the potential risk for addiction. Over 10 years, the National Poison Data Center found a [1,200% increase in kratom-related exposure reports](https://www.cdc.gov/mmwr/volumes/75/wr/mm7511a1.htm) — from 258 in 2015 to 3,434 in 2025. That includes all types of products. Clinicians who run addiction treatment centers say, over the last year, they’ve seen a rise in patients seeking help to get off 7-OH in particular. But data on the most serious risks — overdose and death — are murky. The poison center data showed 233 deaths over the decade, most of which involved other substances like opioids, benzodiazepines, stimulants, and alcohol. (Researchers believe kratom can exacerbate the danger of a drug like fentanyl, and even more common medications like certain antidepressants.) A [2023 investigation by the Tampa Bay Times](https://project.tampabay.com/investigations/deadly-dose/kratom-overdose-deaths-florida-mitragynine-testing/) found that, over nearly 10 years, more than 580 people in Florida alone died from overdoses that involved kratom products. Because both 7-OH and MGPI are metabolites of mitragynine, it can be difficult to draw conclusions about a given death, even with toxicology data. Complicating the matter even further: When tested, many kratom products — natural and synthetic — are found to have [different concentration levels](https://pharmacy.ufl.edu/2026/07/30/whats-behind-the-label-study-finds-inconsistencies-in-commercial-kratom-derived-products/) than the labels advertise, and some have been found to contain compounds that were not on the label at all. Sklar and VanFleet are both proponents of regulations, not bans, on all types of kratom-related products. Others who advocate for natural kratom are working hard to distance themselves from the more synthet
## Related Clinical Research

- [Regulation of Kratom and 7-OH: Experts Call for Action and Debate Solutions](https://medichelpline.com/clinical-feed/stat-news-1-kratom-and-7-oh-should-be-regulated-experts-agree-they-re-split-on-how.md)
- [Renewed Pharma and VC Interest in Osteoporosis Treatments After FDA Shift](https://medichelpline.com/clinical-feed/stat-news-1-stat-drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.